L'intérêt à découvert pour Cerence donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Cerence. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Cerence (NASDAQ:CRNC) Stock, Rapport sur les intérêts à découvert

CERENCE INC

Cerence

Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.

Cerence Inc

Capricorn Energy PLC ADR

CAPRICORN ENRGY U/ADR by CAPRICORN ENERGY PLC

Capricorn Energy PLC

WIIM

RYAM

Rayonier Advanced Materials shares are trading lower following worse-than-expected Q1 financial results.

<ul>
<li>Ginkgo previously issued 2025 guidance for Total revenue of $160-$180 million, Cell Engineering revenue of $110-$130 million; and Biosecurity revenue of at least $50 million.&nbsp; Ginkgo updates its previously issued guidance solely to reflect the impact of the previously mentioned $7 million non-cash deferred revenue release in the first quarter to:
<ul>
<li>Total revenue of $167-$187 million in 2025;</li>
<li>Cell engineering revenue of $117-$137 million in 2025; and</li>
<li>Biosecurity revenue of at least $50 million in 2025.</li>
</ul>
</li>
</ul>

News

Guidance

Ginkgo Bioworks Holdings Updates FY2025 Sales Guidance from $160.00M-$180.00M to $167.00M-$187.00M vs $202.01M Est

Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) lowers FY2025 sales outlook from $670.00 million-$710.00 million to $660.00 million-$690.00 million vs $671.64 million estimate.

CVGI

Commercial Vehicle Group Lowers FY2025 Sales Guidance from $670.00M-$710.00M to $660.00M-$690.00M vs $671.64M Est

Significant Recent Developments
Construction
<ul>
<li>Under the EPC contracts with Bechtel Energy Inc. (Bechtel), Phase 1 progress is tracked for Train 1, Train 2, and the common facilities on a combined basis and Train 3 on a separate basis. As of March 2025:</li>
<li>The overall project completion percentage for Trains 1 and 2 and the common facilities of the Rio Grande LNG Facility was 42.8%, which is in line with the schedule under the EPC contract. Within this project completion percentage, engineering was 87.9% complete, procurement was 76.3% complete, and construction was 14.1% complete.</li>
<li>The overall project completion percentage for Train 3 of the Rio Grande LNG Facility was 17.8%, which is also in line with the schedule under the EPC contract. Within this project completion percentage, engineering was 41.9% complete, procurement was 37.2% complete, and construction was 0.8% complete.</li>
<li>In February 2025, the Company provided additional information regarding its development of additional liquefaction capacity at the Rio Grande LNG Facility beyond Trains 1 through 5. Trains 6 through 8 are wholly owned by NextDecade and are cumulatively expected to increase the Company's total liquefaction capacity by approximately 18 million tonnes per annum (MTPA) once constructed and placed into operation.</li>
<li>Train 6, with expected LNG production capacity of approximately 6 MTPA, is being developed inside the existing levee at the site and adjacent to Trains 1 through 5. A pre-filing application with FERC for Train 6 is expected in 2025, and a full FERC application is expected in early 2026.</li>
<li>Trains 7 and 8, with a total expected LNG production capacity of approximately 12 MTPA, are being developed on the site outside of the existing levee.</li>
</ul>
Strategic and Commercial
<ul>
<li>In January 2025, the Company requested a pricing refresh under the August 2024 EPC contract with Bechtel for Train 4 and related infrastructure. The pricing refresh is in process and is expected to be completed in the second quarter of 2025.</li>
<li>In April 2025, the Company announced a 20-year LNG SPA with a subsidiary of Saudi Aramco (Aramco), pursuant to which the Aramco subsidiary will purchase 1.2 MTPA of LNG From Train 4 at the Rio Grande LNG Facility for 20 years, on a free on board (FOB) basis at a price indexed to Henry Hub, subject to a positive FID on Train 4.</li>
<li>In April 2025, the Company announced that TotalEnergies exercised its LNG purchase option with respect to Train 4 and the Company entered into a 20-year LNG SPA with TotalEnergies, pursuant to which TotalEnergies will purchase 1.5 MTPA of LNG from Train 4 at the Rio Grande LNG Facility for 20 years, on an FOB basis at a price indexed to Henry Hub, subject to a positive FID on Train 4. The Company believes sufficient long-term commercial agreements are now in place to support a positive FID on Train 4.</li>
</ul>
Financial
<ul>
<li>In April 2025, Rio Grande LNG, LLC elected to terminate $250 million of commitments under its working capital facility due to a decrease in expected requirements for credit support during construction, which reduced the outstanding commitments under the working capital facility to $250 million and is expected to reduce related commitment fees by approximately $2 million annually.</li>
</ul>
Regulatory
<ul>
<li>In March 2025, the U.S. Court of Appeals for the D.C. Circuit issued a revision to its August 2024 decision regarding the Company's FERC order, resulting in a remand without vacatur of the FERC order for the first five liquefaction trains at the Rio Grande LNG Facility. Pursuant to the remand, FERC is to consider the issue of an SEIS in view of several executive orders issued since January 20, 2025.</li>
<li>In March 2025, the FERC issued a draft SEIS for the first five liquefaction trains at the Rio Grande LNG Facility. A final SEIS is expected in July 2025.</li>
</ul>

NextDecade Provides Q1 And Early Q2 2025 Business Update

LFVN

Lifevantage shares are trading lower following a Q3 sales miss and after the company cut its FY25 sales guidance below estimates.

Earnings

Earnings Beats

Ginkgo Bioworks Holdings Q1 EPS $(1.68) Beats $(1.69) Estimate, Sales $48M Beat $43.12M Estimate

Dundee Precious Metals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DPM#TSX">DPM</a>) reported quarterly earnings of $0.32 per share. This is a 77.78 percent increase over earnings of $0.18 per share from the same period last year. The company reported $144.15 million in sales this quarter. This is a 16.44 percent increase over sales of $123.79 million the same period last year.

TSX:DPM

Dundee Precious Metals Q1 Adj. EPS $0.32 Up From $0.18 YoY, Sales $144.15M Up From $123.79M YoY

Goldman Sachs analyst Mark Delaney maintained a Neutral rating on Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a <a target="_blank" href="https://in.benzinga.com/quote/TSLA/analyst-ratings" rel="noreferrer noopener">price forecast of $235</a> on Monday.
Delaney commented that Tesla&#8217;s ability to leverage its Full Self Driving (FSD) software in China would be important for the stock going forward, given the size of the China vehicle market, the increasingly competitive landscape for ADAS software and robotaxi offerings in the region, and the role that future profits from AI-enabled products like FSD have for Tesla&#8217;s valuation.&nbsp;&nbsp;
China is the biggest car market in the world.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44607859/teslas-deliveries-slide-in-q1-amid-production-setbacks-political-backlash" rel="noreferrer noopener">Tesla&#8217;s Deliveries Slide In Q1 Amid Production Setbacks, Political Backlash</a>
Additionally, the analyst noted it had become the biggest market for Tesla&#8217;s new vehicle sales over the last year. Delaney attributed this in part to the market size in China, where BEV penetration rates are higher.
However, the analyst also cited that changes in market share have played a role. While Tesla&#8217;s trailing twelve-month share in the U.S. BEV market has fallen to about 45% as of the first quarter, and its share in Europe has fallen to the low double-digit range, Tesla&#8217;s BEV share in China has been more stable in the high single-digit range.
On February 25, media outlets reported that Tesla had pushed an update to some users who had previously purchased Tesla&#8217;s FSD software with several FSD-like features, including automatic lane change, traffic light detection, and turning capabilities.
Tesla commented on its first-quarter 2025 earnings call that it could launch supervised FSD in China with minimal local-specific data for the Chinese market, as the company could leverage the more generalized software it had already developed.
According to media reports, Tesla&#8217;s FSD software has historically worked better in the U.S., as Tesla has had more data and time to refine its products domestically. Tesla also spoke about the benefits of local training and parameters on its first-quarter 2025 call.
FSD in China has performed relatively well, especially given the limits to Tesla&#8217;s data collection in China. However, some reviews cite a lack of understanding of local traffic rules and the sporadic use of wrong lanes, which Delaney noted could be due to the more limited data for the Chinese market.
Tesla&#8217;s FSD offering is one of several ADAS options for consumers in China, with many local competitors offering this as a standard feature even on mainstream vehicles. The level of technology and cost improvement that Tesla can achieve with FSD, both absolute and relative to competitors, will be key for its longer-term economics related to autonomy (both globally and in China).
The analyst noted that there have also been media reports that China is looking to regulate better how companies test, deploy, and market smart driving features.
Delaney remarked that Tesla hopes to offer robotaxi services widely over time, but it plans to do this first in Texas, starting in June 2025. For the U.S. market, the analyst noted that the cost of Tesla&#8217;s vehicles could be an advantage over other robotaxi offerings. Specifically, its cost of goods sold per vehicle globally was about $35.5K in the first quarter of 2025, and per Tesla, its more recent Hardware 4 equipped vehicles have all of the hardware needed for L4.
If Tesla eventually starts a robotaxi operation in China, it will face a different competitive landscape with several autonomous vehicles having attractive costs. Delaney stated that technology development, scale/cost, and regulatory approvals will be key factors in monitoring and assessing Tesla&#8217;s success with robotaxis in the region.&nbsp;&nbsp;
Delaney projected fiscal 2025 revenue of $93.17 billion and EPS of $1.20.
Price Action: TSLA stock closed lower by 1.75% to $275.35 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44850615/teslas-future-growth-from-robotaxis-and-new-products-intact-despite-q1-miss-analyst" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Future Growth From Robotaxis And New Products Intact Despite Q1 Miss: Analyst</a></li>
</ul>
Image via Shutterstock

Analyst Color

Price Target

Reiteration

Analyst Ratings

Tech

Trading Ideas

TSLA

Tesla's Future Hinges On China FSD: Goldman Sachs

Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 200 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $169.79 million which beat the analyst consensus estimate of $164.54 million by 3.19 percent. This is a 12.76 percent decrease over sales of $194.63 million the same period last year.

Commercial Vehicle Group Q1 Adj. EPS $(0.08), Inline, Sales $169.79M Beat $164.54M Estimate

Russel Metals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RUS#TSX">RUS</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.58 by 29.31 percent. This is a 8.54 percent decrease over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $1.17 billion which beat the analyst consensus estimate of $1.14 billion by 2.98 percent. This is a 10.65 percent increase over sales of $1.06 billion the same period last year.

TSX:RUS

Russel Metals Q1 EPS $0.75 Beats $0.58 Estimate, Sales $1.17B Beat $1.14B Estimate

WW International shares are trading lower after the company missed its Q1 adjusted EPS estimate and announced it will not be providing FY25 guidance.

Corpay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) reported quarterly earnings of $4.51 per share which met the analyst consensus estimate. This is a 10 percent increase over earnings of $4.10 per share from the same period last year. The company reported quarterly sales of $1.01 billion which missed the analyst consensus estimate of $1.02 billion by 0.98 percent. This is a 7.56 percent increase over sales of $935.25 million the same period last year.

Earnings Misses

CPAY

Corpay Q1 Adj. EPS $4.51, Inline, Sales $1.01B Miss $1.02B Estimate

Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.53) by 32.08 percent. This is a 95.36 percent increase over losses of $(7.76) per share from the same period last year. The company reported $1.45 million in sales this quarter.

BIOA

Bioage Labs Q1 EPS $(0.36) Beats $(0.53) Estimate, Sales $1.45M

Kinross Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.23 by 30.43 percent. This is a 200 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $1.50 billion which beat the analyst consensus estimate of $1.43 million by 105.02K percent. This is a 38.51 percent increase over sales of $1.08 billion the same period last year.

Kinross Gold Q1 Adj. EPS $0.30 Beats $0.23 Estimate, Sales $1.50B Beat $1.43M Estimate

VSTE

Vast Renewables shares are trading lower after the company announced it voluntarily delisted from the Nasdaq.

InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect InflaRx to report an earnings per share (EPS) of $-0.17.
The market awaits InflaRx's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.19 in the last quarter, leading to a 1.59% increase in the share price on the following day.
Here's a look at InflaRx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.28</td>
<td>-0.27</td>
<td>-0.21</td>
<td>-0.24</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.09</td>
<td>-0.33</td>
<td>-0.26</td>
<td>-0.18</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>3.0%</td>
<td>3.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746565298_0.png" alt="eps graph" />
<h3>Performance of InflaRx Shares</h3>
Shares of InflaRx were trading at $1.65 as of May 05. Over the last 52-week period, shares are up 34.17%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/IFRX/earnings">To track all earnings releases for InflaRx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IFRX

Preview: InflaRx's Earnings

In the last three months, 9 analysts have published ratings on NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated NeoGenomics and provided 12-month price targets. The average target is $12.94, accompanied by a high estimate of $18.00 and a low estimate of $8.50. This current average represents a 31.1% decrease from the previous average price target of $18.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1746565266_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of NeoGenomics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$9.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.50</td>
<td>$18.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NeoGenomics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NeoGenomics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of NeoGenomics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NEO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NeoGenomics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into NeoGenomics's Background</h2>
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
<h3>Unraveling the Financial Story of NeoGenomics</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: NeoGenomics's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 7.55%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: NeoGenomics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -15.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NeoGenomics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -2.9%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.6%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: NeoGenomics's debt-to-equity ratio is below the industry average. With a ratio of 0.68, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing NeoGenomics: Insights From 9 Financial Analysts

One year ago, we established a concentrated position in shares of&nbsp;CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>). Since our purchases in May 2024,&nbsp;CVS shares have generated a total return of 25% reflecting initial progress in the long-term cultural and operational turnaround underway at the Company. &nbsp;Our position size afforded us the scale necessary to constructively engage with the Board, Management, and fellow Shareholders in Q3 2024 on a multi-faceted performance improvement plan:
<ol>
<li>Board Refreshment&nbsp;– The Board welcomed four new Directors including Larry Robbins, Glenview's CEO, and recently appointed a strong Lead Independent Director.&nbsp; The entire Board is operating cooperatively and cohesively; &nbsp;</li>
<li>Strengthening Culture and Leadership&nbsp;– CVS's leadership has undergone significant transformation under new CEO David Joyner's leadership, combining internal promotion with external recruitment while strengthening a customer-centric, accountable culture; &nbsp;</li>
<li>Operational Intensity&nbsp;– CVS exceeded consensus earnings expectations over the past two quarters and has seen operating strength and early signs of recovery across its businesses; &nbsp;</li>
<li>Risk Management&nbsp;– The Company has suspended material acquisitions, committed to deleveraging, strengthened its insurance reserve levels and established a clear path to sustainable returns on capital that will fuel future customer service and benefit stability; &nbsp;</li>
<li>Portfolio Enhancement and Innovation&nbsp;– CVS has exited or transitioned certain lines of business where economics prevent a sustainable commitment to customers while leading the industry with transparent and value-added solutions to reduce cost and complexity; and &nbsp;</li>
<li>Opportunistic Capital Deployment&nbsp;– In combination, CVS has marched closer to the time in which share repurchase can be both a responsible consideration and a creator of long-term shareholder value.&nbsp;</li>
</ol>
Following healthy Q1 results and increased annual guidance, Glenview reduced its overall holdings by 3.75 million shares consistent with our fund's diversification parameters and to create buying power for further unique opportunities in this volatile macro environment.&nbsp;With this rebalancing, CVS Health remains our largest position, and we have no plans for additional adjustments to our CVS holdings.&nbsp; Our confidence in the near, medium, and long-term outlook for CVS remains strong.&nbsp;
We are grateful for the engagement and enthusiasm of the entire CVS Health team in the revitalization efforts well underway and are fully committed to making continued contributions to the vitality and long-term success of this iconic institution that strengthens the health of 185 million people.
Together we grow.
&nbsp;

Management

Glenview Capital Issues Statement On CVS Health; Highlights 25% Return On CVS Health Investment Since May 2024 As Turnaround Gains Traction, Citing Board Refresh, Cultural And Leadership Overhaul Under New CEO, Operational Gains, Deleveraging, Strategic Business Exits, And Renewed Capital Discipline; Says CVS Remains Firm's Largest Holding After Modest Rebalancing

Electronic Arts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) released its fourth-quarter results after Tuesday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/05/b45235130/electronic-arts-reports-q4-and-fy25-results">from the quarter.</a>
The Details: Electronic Arts reported quarterly earnings of $1.58 per share, which beat the analyst consensus estimate of $1.09. Quarterly revenue clocked in at $1.8 billion, beating the consensus estimate of $1.56 billion.
Read Next:&nbsp; <a href="https://www.benzinga.com/news/legal/25/05/45226604/president-trump-wants-to-reopen-alcatraz-heres-what-it-would-take?utm_source=articleShare">President Trump Wants To Reopen Alcatraz: Here&#8217;s What It Would Take</a>
For the fourth quarter and fiscal year, Electronic Arts reported: 
<ul>
<li>Net bookings of $7.355 billion.</li>
<li>The EA SPORTS portfolio delivered another record net bookings year. </li>
<li>EA&#8217;s American Football franchise reached over $1 billion in net bookings. </li>
<li>The Sims franchise saw double-digit growth in the quarter.</li>
<li>In EA SPORTS FC, player monetization was up double digits, starting with the mid-January gameplay update.</li>
<li>Split Fiction has sold nearly 4 million units since its launch in March.</li>
</ul>
&#8220;The incredible success of College Football and the enduring strength of FC drove another record year for EA SPORTS, while The Sims capped FY25 with a historic Q4,&#8221; said Andrew Wilson, CEO of Electronic Arts. 
&#8220;As we look to the future, we&#8217;re confident in our ability to execute across a deep pipeline — beginning this summer with the highly anticipated reveal of Battlefield, a pivotal step in delivering on our next generation of blockbuster entertainment,&#8221; Wilson added. 
Outlook:&nbsp;The company expects fiscal year 2026 net bookings to be approximately $7.6 billion to $8 billion and net revenue to be approximately $7.1 billion to $7.5 billion. 
EA Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Electronic Arts stock was up 5.47% after-hours at $163 on Tuesday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45228179/upwork-delivers-solid-start-to-2025-analyst?utm_source=articleShare">Upwork Delivers &#8216;Solid Start To 2025&#8217;: Analyst&nbsp;</a></li>
</ul>
Image: Shutterstock

Gaming

After-Hours Center

Movers

General

Electronic Arts Stock Climbs After Better-Than-Expected Q4 Report

In the preceding three months, 13 analysts have released ratings for Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Foot Locker and provided 12-month price targets. The average target is $18.85, accompanied by a high estimate of $24.00 and a low estimate of $12.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 13.09%. 
<img src="https://www.benzinga.com/files/images/story/2025/1746565251_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Foot Locker among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Foot Locker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Foot Locker compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Foot Locker's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Foot Locker's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Foot Locker analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Foot Locker</h2>
Foot Locker Inc operates footwear and apparel retailer in North America, Europe, Australia, New Zealand, and Asia, and has licensed store presence in the Middle East, Europe, and Asia. The company mainly sells athletically inspired shoes and apparel. Foot Locker's merchandise comes from only a few suppliers, with Nike providing the majority. Its portfolio of brands includes Foot Locker, Kids Foot Locker, Champs Sports, WSS, and atmos. The company has omnichannel capabilities to bridge the digital world and physical stores, including order-in-store, buy online and pickup-in-store, and buy online and ship-from-store, as well as e-commerce. It has three operating segments, North America, EMEA, and Asia Pacific.
<h3>Foot Locker's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Foot Locker's financials over 3M reveals challenges. As of 31 January, 2025, the company experienced a decline of approximately -5.7% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Foot Locker's net margin is impressive, surpassing industry averages. With a net margin of 2.18%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Foot Locker's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.7%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Foot Locker's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.72%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.96.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

13 Analysts Assess Foot Locker: What You Need To Know

Press Releases

Cerence Announces First Quarter Fiscal 2025 Results

Cerence AI Debuts xUI, its Hybrid, LLM-Based Platform, Advancing the Fully Agentic In-Car Experience

Cerence AI Adds Former Ford Executive Marion Harris to its Board of Directors

Cerence AI Honored with 2025 ECARX Best Contribution Award

Cerence AI Honored with HARMAN's Best Technology Award

Cerence to Announce Fiscal Second Quarter Results on May 7, 2025

Auto Shanghai 2025: Cerence AI Partners with Industry Leaders to Showcase xUI, its Hybrid, Agentic AI Assistant Platform

Cerence AI and MediaTek Partner to Introduce Multi-Modal Language Models Running on the Edge, Built on NVIDIA

Cerence AI and Code Factory Collaborate to Bring Voice-Powered Interaction to Self-Service Kiosks

Legal

Cerence AI Files Copyright Infringement Suit Against Microsoft and Nuance

CRNC

Agora

Digital Turbine

Bit Digital

Consensus Cloud Solutions, Inc. - Common Stock

Consensus Cloud Solns

Daily Journal Corp. (S.C.) - Common Stock

Daily Journal

Digimarc

Domo

E2open Parent Holdings, Inc.Class A Common Stock

E2open Parent Holdings

BitFuFu

Gorilla Technology Group Inc. - Ordinary shares

Gorilla Tech Gr

AMTD Digital Inc. American Depositary Shares (every five of which represent two Class A Ordinary Shares)

Comments

Cerence

Intérêt court

Cerence (NASDAQ:CRNC) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL